From Pre-Approval Inspection (PAI) to Complete Response Letter (CRL): A Data-Driven Review of CRL Risk
Thursday, February 12, 2026
8:00 AM PT / 11:00 AM ET
Complete Response Letters (CRLs) are being published more frequently, and the data show that facility and CMC deficiencies remain among the leading drivers of delayed approvals.
In this webinar, Redica and Eliquent experts will examine CRL events from 2022 – 2025, exploring how pre-approval inspections, Form 483 observations, and inspection timing patterns intersect to create approval risk.
Our speakers go beyond publicly available FDA data to link CRLs directly to inspections, quantify key risk factors, and surface recurring quality system breakdowns that continue to trigger CRLs, particularly at shared manufacturing sites.
If your organization is preparing for, supporting, or responding to a pre-approval inspection, this session will provide data-driven insight into where FDA scrutiny is intensifying and why remediation efforts often fall short.
Key Highlights:
- CRL trends from 2022–2025, including the growing role of FDA transparency
- How PAIs, Form 483 findings, and inspection timing influence CRL outcomes (and which inspection signals matter most)
- Which facility inspection and CMC deficiencies most often delay approvals
- How inspection risk differs for sponsors versus CMOs/CDMOs (and why shared facilities amplify exposure)
- Why late inspections and ineffective CAPAs lead to repeat CRLs and limited remediation runway